Barry Meier

Barry Meier is a New York Times reporter and the author of Pain Killer, whose work carries the story of OxyContin from rural drug investigations into questions of corporate accountability, medical oversight, and family loss. In the book’s reporting, he is not only a chronicler of a drug epidemic but also an investigator of the gaps between what families need to know and what law enforcement can prove. His account moves between documents, courtrooms, drug networks, and the unresolved questions left by individual deaths.

Reporting OxyContin’s spread

On February 9, 2001, Meier and a colleague brought the OxyContin epidemic to the front page of The New York Times with a story about Operation OxyFest, a nine-month federal investigation near Lee County. The investigation had produced what authorities described as the largest drug-abuse raid in Kentucky history. A federal prosecutor reported that 207 user-dealers had been caught, most of them patients who had obtained pills from doctors described as busy, careless, or quietly cooperative in overprescribing. The scale of the arrests showed how far the problem extended beyond a handful of conspicuous dealers; investigators acknowledged that they had not caught even half of those involved.

The story appeared as the epidemic was spreading across Appalachia and beyond. OxyContin abuse and related crime were drawing headlines in places from Miami–Dade County to Bridgeport, Connecticut, while teenagers in suburban communities were passing assorted pills around at so-called pharm parties. Meier’s reporting helped make a rural crisis legible to a national audience at a moment when its consequences were appearing in communities with very different public images. The book’s account presents this shift not as a sudden discovery of a new problem, but as a widening recognition of harm already under way.

From a book to questions about accountability

Meier’s Pain Killer became part of the information families used to understand the drug that had entered their lives through loss. After her twenty-four-year-old son Patrick died in 2004 following his first and only OxyContin at a Fourth of July party, Barbara Van Rooyan contacted Ed Bisch, who connected her with Art Van Zee. Having read Meier’s account of Van Zee’s conflict with Purdue Pharma, Van Rooyan wanted to know how such a powerful drug had been approved for sale.

Van Zee answered with the history and paperwork behind the approval. He had a copy of Purdue’s New Drug Application, given to him by Sue Ella Kobak in 2000. The review, led by Curtis Wright, described how crushing a tablet could release the medication immediately rather than as intended over time; it also recorded withdrawal symptoms during clinical trials and stated that 68 percent of the oxycodone in a crushed pill could be recovered for injection. The approval summary advised caution in promotional materials, while Wright later worked as a consultant for Purdue Pharma. By placing these details in a conversation prompted by a bereaved mother’s question, Meier’s reporting made regulatory documents answerable to the people living with the consequences of the drug’s approval.

Van Zee also recounted to Van Rooyan his January 2002 drive to an advisory committee meeting of the U.S. Food and Drug Administration. He went to challenge evidence about OxyContin’s addiction risk, facing Purdue executives and prominent pain-management experts, most of whom acknowledged having been paid speakers for the company. Outnumbered nineteen to one and uneasy with public speaking, Van Zee nevertheless regarded his testimony as a responsibility. Meier’s account of that encounter shows how a local doctor’s objections became part of a larger dispute over who had the authority to define the drug’s risks.

Pressure on the press and the criminal investigation

Meier’s coverage brought him into conflict with Purdue Pharma. After the publication of Pain Killer, company lawyer Howard Udell complained to The New York Times editors that Meier had a conflict of interest because his book gave him a financial stake in continued coverage. Udell wanted him removed from the beat. Meier later described the company’s aim as suppressing news coverage. He also suspected that Purdue was already under criminal investigation, a fact the company had not disclosed during its effort to challenge his standing as a reporter.

The effort to discredit Meier had a lasting effect on his newspaper coverage. With two limited, technical exceptions, he did not write about Purdue Pharma for The New York Times again for four years. One story concerned an OxyContin patent ruling; another concerned a possible drug-company purchase. Meanwhile, John Brownlee had read Pain Killer and knew about Purdue’s attempt to pressure Meier. Soon after becoming U.S. attorney, Brownlee began investigating Purdue, though the investigation was not made public until 2005. The sequence does not make Meier the cause of the prosecution, but it places his reporting among the accounts that had made the company’s conduct a matter of public scrutiny.

Purdue also hired former New York mayor Rudy Giuliani and his consulting firm as it faced lawsuits, investigations, and public-relations problems. Giuliani was tasked with reassuring public officials that Purdue could be trusted. He negotiated behind the scenes over a fine related to the company’s New Jersey manufacturing plant: the Purdue affiliate agreed to a $2 million civil penalty without admitting wrongdoing, while a Drug Enforcement Administration diversion-control manager had argued for a $10 million fine. The episode gave Meier’s reporting a wider institutional frame: corporate reputation, regulatory enforcement, and access to political influence all mattered alongside the medical evidence about the drug.

Witnessing the legal reckoning

Meier followed the case beyond the investigation and into court. When Purdue executives Howard Udell, Paul Goldenheim, and Michael Friedman first visited Abingdon to deliver guilty pleas, Meier arrived the previous night and waited near their hotel with a freelance photographer hired by The New York Times. He had interviewed the men in their offices and by telephone, but wanted to witness their appearance in person. At a later courthouse visit, Judge James P. Jones ordered the executives to enter through the front door like everyone else. Meier stood to one side and watched. It was his fifty-eighth birthday, and he regarded the occasion as a fitting gift: a reporter who had covered the dispute could now observe its public legal consequences in the region most affected.

Meier’s account of the prosecution is also about the difficulty of turning a broad pattern into a provable case. The 2001 story had shown the reach of OxyContin abuse through a major investigation; the later federal case and court appearances gave the story a different scale, one measured in corporate defendants, legal proceedings, and the limits of punishment. In the book’s treatment of the eventual outcome, Meier reflected that what he had written had been justified. That response registers not a simple triumph but the accumulated significance of years of reporting after the company had tried to curb it.

Individual grief and the limits of proof

The book’s reporting frame begins with a grieving mother’s demand to understand how her son died. Meier goes to prison to speak with Ronnie Jones, who had run a large drug ring, because Kristi Fernandez wants to know what led to the death of her nineteen-year-old son, Jesse Bolstridge. Her search is not satisfied by tending Jesse’s grave. She wants to reconstruct the swift progression from a high-school football player and construction worker to a fatal heroin overdose, in the hope that a clearer account might help other parents protect their children.

Meier carries that question into an investigation broader than one dealer or one death. He describes how users who begin with pills can turn to heroin, then sell portions of what they buy to finance the next purchase. Withdrawal makes the cycle urgent, while users recruiting other customers allows it to multiply. This structural account helps explain how a local market can grow, but it does not erase the difference between describing a network and establishing responsibility for a particular death.

That distinction remains explicit in the account of Jesse’s case. Investigators believed that Dennis Painter, Jesse’s best friend, had bought the heroin from a local user-dealer whose supply came from people in the Jones and Shaw ring. But roughly eighteen hours separated Dennis’s purchase from Jesse’s death, and other people and unknown circumstances intervened. The timeline was not conclusive enough to establish who supplied the dose that killed him. Meier records the uncertainty rather than converting a plausible connection into certainty. The unresolved evidence is part of the story: families seek a clear explanation, while overdose investigations often confront a fluid chain of transactions and limited resources.

Across these strands, Meier’s role is to make distant systems and intimate losses visible in the same narrative. A federal raid, a regulatory application, a corporate effort to pressure a newspaper, and a mother’s questions about her son’s grave are not interchangeable forms of evidence, but his reporting places them in conversation. The result is an account attentive both to the scale of the epidemic and to the limits of what a journalist, a family, or a prosecutor can finally know about one death.